Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)
Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs...
Gespeichert in:
Veröffentlicht in: | Revista española de quimioterapia 2023-08, Vol.36 (4), p.400-407 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 407 |
---|---|
container_issue | 4 |
container_start_page | 400 |
container_title | Revista española de quimioterapia |
container_volume | 36 |
creator | Risco-Risco, C Martínez-Urbistondo, D Suárez Del Villar, R Ayerbe García-Monzón, L Pérez-Rubio, A Barberán-López, J Andaluz-Ojeda, D Villares Fernández, P |
description | Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs).
Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine.
Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose.
Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection. |
doi_str_mv | 10.37201/req/017.2023 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10336310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2807918732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-90813d1d4d3273d39c17036d112b8c4a238c38dc392016fe9166c03f95938fd33</originalsourceid><addsrcrecordid>eNpVkc9u1DAQxi0EosvCkSvysRzS2p40sU-oivizUqUegF4t13Y2hsRObWfRvhS8A0-Gd1squMxoPD9938gfQq8pOYOWEXoe7d05oe0ZIwyeoBUVnFfigvKnaEUYrSuomThBL1L6RkgNtaDP0Qm0lAoKZIV-bXw_LtZri0OP7eyMnVwYw9ZpNWLlDdaj88ehVzqHmLDzOA8WR3uYt7YsXd7jHHAXJhe9yvvfP_FOae28PcCDVWMesFbR4h8hfrdFo3gp_HlW3qUBL97tyuNRpYgOzm_xENLscnE97a5vNjeXHU55Mfu3L9GzXo3Jvnroa_T1w_sv3afq6vrjpru8qjTUda4E4RQMNbUB1oIBoWlLoDGUsluua8WAa-BGgyhf2PRW0KbRBHpxIYD3BmCN3t3rzsvtZI22Pkc1yjm6ScW9DMrJ_zfeDXIbdpISgAZKXaPTB4UY7habspxc0nYclbdhSZJx0grKW2AFre5RHUNK0faPPpTIY8qypCxLyvKQcuHf_HvcI_03VvgD9SmnPw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2807918732</pqid></control><display><type>article</type><title>Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Risco-Risco, C ; Martínez-Urbistondo, D ; Suárez Del Villar, R ; Ayerbe García-Monzón, L ; Pérez-Rubio, A ; Barberán-López, J ; Andaluz-Ojeda, D ; Villares Fernández, P</creator><creatorcontrib>Risco-Risco, C ; Martínez-Urbistondo, D ; Suárez Del Villar, R ; Ayerbe García-Monzón, L ; Pérez-Rubio, A ; Barberán-López, J ; Andaluz-Ojeda, D ; Villares Fernández, P</creatorcontrib><description>Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs).
Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine.
Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose.
Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.</description><identifier>ISSN: 0214-3429</identifier><identifier>EISSN: 1988-9518</identifier><identifier>DOI: 10.37201/req/017.2023</identifier><identifier>PMID: 37119130</identifier><language>eng</language><publisher>Spain: Sociedad Española de Quimioterapia</publisher><subject>BNT162 Vaccine ; Cohort Studies ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - adverse effects ; Drug-Related Side Effects and Adverse Reactions ; Female ; Health Personnel ; Hospitals, Teaching ; Humans ; Original ; Prospective Studies ; SARS-CoV-2 ; Universities ; Vaccines</subject><ispartof>Revista española de quimioterapia, 2023-08, Vol.36 (4), p.400-407</ispartof><rights>The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</rights><rights>The Author 2023 2023</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336310/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336310/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37119130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Risco-Risco, C</creatorcontrib><creatorcontrib>Martínez-Urbistondo, D</creatorcontrib><creatorcontrib>Suárez Del Villar, R</creatorcontrib><creatorcontrib>Ayerbe García-Monzón, L</creatorcontrib><creatorcontrib>Pérez-Rubio, A</creatorcontrib><creatorcontrib>Barberán-López, J</creatorcontrib><creatorcontrib>Andaluz-Ojeda, D</creatorcontrib><creatorcontrib>Villares Fernández, P</creatorcontrib><title>Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)</title><title>Revista española de quimioterapia</title><addtitle>Rev Esp Quimioter</addtitle><description>Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs).
Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine.
Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose.
Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.</description><subject>BNT162 Vaccine</subject><subject>Cohort Studies</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines - administration & dosage</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Female</subject><subject>Health Personnel</subject><subject>Hospitals, Teaching</subject><subject>Humans</subject><subject>Original</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><subject>Universities</subject><subject>Vaccines</subject><issn>0214-3429</issn><issn>1988-9518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc9u1DAQxi0EosvCkSvysRzS2p40sU-oivizUqUegF4t13Y2hsRObWfRvhS8A0-Gd1squMxoPD9938gfQq8pOYOWEXoe7d05oe0ZIwyeoBUVnFfigvKnaEUYrSuomThBL1L6RkgNtaDP0Qm0lAoKZIV-bXw_LtZri0OP7eyMnVwYw9ZpNWLlDdaj88ehVzqHmLDzOA8WR3uYt7YsXd7jHHAXJhe9yvvfP_FOae28PcCDVWMesFbR4h8hfrdFo3gp_HlW3qUBL97tyuNRpYgOzm_xENLscnE97a5vNjeXHU55Mfu3L9GzXo3Jvnroa_T1w_sv3afq6vrjpru8qjTUda4E4RQMNbUB1oIBoWlLoDGUsluua8WAa-BGgyhf2PRW0KbRBHpxIYD3BmCN3t3rzsvtZI22Pkc1yjm6ScW9DMrJ_zfeDXIbdpISgAZKXaPTB4UY7habspxc0nYclbdhSZJx0grKW2AFre5RHUNK0faPPpTIY8qypCxLyvKQcuHf_HvcI_03VvgD9SmnPw</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Risco-Risco, C</creator><creator>Martínez-Urbistondo, D</creator><creator>Suárez Del Villar, R</creator><creator>Ayerbe García-Monzón, L</creator><creator>Pérez-Rubio, A</creator><creator>Barberán-López, J</creator><creator>Andaluz-Ojeda, D</creator><creator>Villares Fernández, P</creator><general>Sociedad Española de Quimioterapia</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230801</creationdate><title>Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)</title><author>Risco-Risco, C ; Martínez-Urbistondo, D ; Suárez Del Villar, R ; Ayerbe García-Monzón, L ; Pérez-Rubio, A ; Barberán-López, J ; Andaluz-Ojeda, D ; Villares Fernández, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-90813d1d4d3273d39c17036d112b8c4a238c38dc392016fe9166c03f95938fd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>BNT162 Vaccine</topic><topic>Cohort Studies</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines - administration & dosage</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Female</topic><topic>Health Personnel</topic><topic>Hospitals, Teaching</topic><topic>Humans</topic><topic>Original</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><topic>Universities</topic><topic>Vaccines</topic><toplevel>online_resources</toplevel><creatorcontrib>Risco-Risco, C</creatorcontrib><creatorcontrib>Martínez-Urbistondo, D</creatorcontrib><creatorcontrib>Suárez Del Villar, R</creatorcontrib><creatorcontrib>Ayerbe García-Monzón, L</creatorcontrib><creatorcontrib>Pérez-Rubio, A</creatorcontrib><creatorcontrib>Barberán-López, J</creatorcontrib><creatorcontrib>Andaluz-Ojeda, D</creatorcontrib><creatorcontrib>Villares Fernández, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Revista española de quimioterapia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Risco-Risco, C</au><au>Martínez-Urbistondo, D</au><au>Suárez Del Villar, R</au><au>Ayerbe García-Monzón, L</au><au>Pérez-Rubio, A</au><au>Barberán-López, J</au><au>Andaluz-Ojeda, D</au><au>Villares Fernández, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)</atitle><jtitle>Revista española de quimioterapia</jtitle><addtitle>Rev Esp Quimioter</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>36</volume><issue>4</issue><spage>400</spage><epage>407</epage><pages>400-407</pages><issn>0214-3429</issn><eissn>1988-9518</eissn><abstract>Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs).
Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine.
Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose.
Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.</abstract><cop>Spain</cop><pub>Sociedad Española de Quimioterapia</pub><pmid>37119130</pmid><doi>10.37201/req/017.2023</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0214-3429 |
ispartof | Revista española de quimioterapia, 2023-08, Vol.36 (4), p.400-407 |
issn | 0214-3429 1988-9518 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10336310 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | BNT162 Vaccine Cohort Studies COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects Drug-Related Side Effects and Adverse Reactions Female Health Personnel Hospitals, Teaching Humans Original Prospective Studies SARS-CoV-2 Universities Vaccines |
title | Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-10T11%3A15%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20epidemiological%20and%20clinical%20factors%20in%20the%20reactogenicity%20to%20Comirnaty%C2%AE%20vaccine%20in%20health%20care%20workers%20of%20a%20Spanish%20university%20teaching%20hospital%20(COVIVAC%20study)&rft.jtitle=Revista%20espa%C3%B1ola%20de%20quimioterapia&rft.au=Risco-Risco,%20C&rft.date=2023-08-01&rft.volume=36&rft.issue=4&rft.spage=400&rft.epage=407&rft.pages=400-407&rft.issn=0214-3429&rft.eissn=1988-9518&rft_id=info:doi/10.37201/req/017.2023&rft_dat=%3Cproquest_pubme%3E2807918732%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2807918732&rft_id=info:pmid/37119130&rfr_iscdi=true |